Behrad Derakhshan - Aug 12, 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role: Chief Business Officer
Signature: /s/ John R Moore Attorney-in-Fact for Behrad Derakhshan
Stock symbol: EWTX
Transactions as of: Aug 12, 2025
Transactions value $: -$33,360
Form type: 4
Date filed: 8/14/2025, 07:43 PM
Previous filing: May 7, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Derakhshan Behrad	Chief Business Officer	C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER	/s/ John R Moore Attorney-in-Fact for Behrad Derakhshan	2025-08-14	0001853109

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EWTX	Common Stock	Options Exercise	$0	+5.78K	+28.4%	$0.00	26.1K	Aug 12, 2025	Direct
transaction	EWTX	Common Stock	Sale	-$33.4K	-2.49K	-9.53%	$13.39	23.6K	Aug 12, 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EWTX	Restricted Stock Units	Options Exercise	$0	-5.78K	-25%	$0.00	17.3K	Aug 12, 2025	Common Stock	5.78K	$0.00	Direct	F3
transaction	EWTX	Restricted Stock Units	Award	$0	+30K		$0.00	30K	Aug 12, 2025	Common Stock	30K	$0.00	Direct	F4
transaction	EWTX	Stock Option (Right to Buy)	Award	$0	+180K		$0.00	180K	Aug 12, 2025	Common Stock	180K	$13.39	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
F2	The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
F4	Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
F5	1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.